Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

REYATAZ Drug Profile

« Back to Dashboard

Which patents cover Reyataz, and what substitute generic drugs are available?

Reyataz is a drug marketed by Bristol Myers Squibb and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has ninety-three patent family members in forty-two countries.

The generic ingredient in REYATAZ is atazanavir sulfate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. There are seven tentative approvals for this compound. Additional details are available on the atazanavir sulfate profile page.

Summary for Tradename: REYATAZ

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list4
Bulk Api Vendors: see list80
Clinical Trials: see list53
Patent Applications: see list3,173
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:REYATAZ at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
POWDER;ORAL206352-001Jun 2, 2014RXYesYes6,087,383*PED► SubscribeY► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-001Jun 20, 2003DISCNYesNo5,849,911*PED► SubscribeY► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
POWDER;ORAL206352-001Jun 2, 2014RXYesYes► Subscribe► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-003Jun 20, 2003RXYesNo6,087,383*PED► SubscribeY► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-001Jun 20, 2003DISCNYesNo6,087,383*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: REYATAZ

Drugname Dosage Strength RLD Submissiondate
atazanavir sulfateCapsules200 mgReyataz2/16/2010
atazanavir sulfateCapsules100 mg and 150 mgReyataz3/19/2010
atazanavir sulfateCapsules300 mgReyataz7/20/2009

Non-Orange Book Patents for Tradename: REYATAZ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
6,166,004 Combinations of HIV protease inhibitors with reverse transcriptase inhibitors► Subscribe
6,300,519 Antivirally active heterocyclic azahexane derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: REYATAZ

Country Document Number Estimated Expiration
Germany122005000003► Subscribe
New Zealand504417► Subscribe
Argentina014417► Subscribe
Malaysia114838► Subscribe
Poland342019► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: REYATAZ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016039Lithuania► SubscribePRODUCT NAME: ATAZANAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713
2005 00037Denmark► Subscribe
0859Netherlands► SubscribePRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN ATAZANAVIR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER ATAZANAVIRSULFAAT; REGISTRATION NO/DATE: EU/1/15/1025 20150715
C/GB05/036United Kingdom► SubscribeSPC/GB05/036: 20060206, EXPIRES: 20190301
C023/2005Ireland► SubscribeSPC023/2005, 20060612, EXPIRES: 20190301
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc